rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CUE
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      12 Health Care Stocks Moving In Wednesday's Intraday Session
      10h agoBenzingaAKANCUE
      Dow Falls Over 300 Points; Nvidia Posts Upbeat Earnings
      12h agoBenzingaCUE
      B.Riley cuts Cue Biopharma stock price target on financing concerns
      14h agoInvesting.comCUERILYRILYGRILYLRILYNRILYTRILYZ
      Cue Biopharma earnings missed by $3.39, revenue fell short of estimates
      Nov 16Investing.comCUE
      Cue Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
      Nov 16Yahoo FinanceCUE
      Cue Biopharma VP Meluzio sells $32,089 in Cue stock for tax
      Oct 15Investing.comCUE
      Cue Biopharma’s chief legal officer sells $51,724 in stock
      Oct 15Investing.comCUE
      Cue Biopharma CEO Lin Shao-Lee sells $305,490 in shares
      Oct 15Investing.comCUE
      B.Riley reiterates Cue Biopharma stock rating on allergy data
      Oct 1Investing.comCUERILYRILYGRILYLRILYNRILYTRILYZ
      Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response

      Cue Biopharma (NASDAQ:CUE) reported positive top-line results from a Phase II trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, whose disease was inadequately controlled with H1 antihistamines. The randomized, double-blind, placebo-controlled study evaluate

      Sep 28Yahoo FinanceCUE
      Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?
      Sep 26Yahoo FinanceCUE
      Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria - Slideshow (NASDAQ:CUE) 2026-09-24

      2026-09-24. The following slide deck was published by Cue Biopharma, Inc.

      Sep 24Seeking AlphaCUE
      Lift Therapeutics Appoints Daniel Passeri as Chief Executive Officer
      Sep 23Yahoo FinanceCUE
      An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
      Sep 22Yahoo FinanceCUE
      Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOA
      Sep 21Seeking AlphaCUE
      Cue Biopharma plummets on phase 2 data for chronic spontaneous urticaria asset
      Sep 21Seeking AlphaCUE
      What's Going on With Cue Biopharma Stock on Monday? - Cue Biopharma (NASDAQ:CUE)

      Cue Biopharma reports Phase 2 CUE-221 trial results in chronic hives, showing strong efficacy and favorable safety.

      Sep 21BenzingaCUE
      12 Health Care Stocks Moving In Monday's Pre-Market Session - Greenland Mines (NASDAQ:GRML), Cue Biopharm

      Gainers Greenland Mines (NASDAQ:GRML) stock rose 108.1% to $5.93 during Monday's pre-market session. The market value of their outstanding shares is at $9.0 million. Cue Biopharma (NASDAQ:CUE) stock moved upwards

      Sep 21BenzingaCUE
      Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results

      Cue Biopharma (NASDAQ:CUE) shares rose 41. 6% in premarket trading after the company reported positive topline results from a Phase 2 clinical trial evaluating CUE-221 in patients with moderate to severe chronic spontaneous urticaria.

      Sep 21Yahoo FinanceCUE
      Why is Cue Biopharma stock surging today?
      Sep 21Investing.comCUE
      Cue Biopharma Meets Primary Goal in a Phase 2 Study of Chronic Hives Disease Drug Candidate
      Sep 21Yahoo FinanceCUE
      Cue Biopharma reports positive phase 2 results for CUE-221
      Sep 20Investing.comCUE
      Cue Biopharma is a new Buy at B. Riley on valuation
      Sep 18Seeking AlphaCUERILYRILYGRILYLRILYNRILYTRILYZ
      This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
      Sep 18BenzingaCUE
      Cue Biopharma stock initiated at Buy by B.Riley on allergy drug potential
      Sep 18Investing.comCUERILYRILYGRILYLRILYNRILYTRILYZ

      This is the newest page. Registered accounts read further back.